The collapse of private equity's ophthalmology exit market didn't come from ophthalmology; it came from the institutional investors who provided PE fund managers with capital in the first place. State pension systems, sovereign wealth funds, endowments, large foundations, and fund-of-fund allocators are the limited partners behind every major PE platform in American healthcare, and when those LPs changed what they demanded from their fund managers, they changed what was possible for PE platforms to execute. The shift that matters: institutional LPs decided, starting around 2022 and hardening through 2024-2025, that they would no longer accept extended hold periods and continuation vehicles as substitutes for realized distributions. They wanted cash back. They got increasingly willing to punish fund managers who couldn't deliver it. That decision, made in state pension investment offices and institutional allocator meetings far from any ophthalmology practice, structurally killed the exit pathway that the 2017-2019 ophthalmology platform cohort was built to execute, which created the current market where ophthalmology PE platforms are stuck, in stabilization, or pursuing distressed exits rather than clean buyouts at premium multiples. Understanding why pension funds killed the ophthalmology exit, and why that matters for the next generation of the category, requires walking through the capital mechanics that institutional investors actually operate under.

What Institutional LPs Are Demanding

The Institutional Limited Partners Association (ILPA) conducts regular member surveys of institutional LPs investing in private equity. ILPA's 2024 member survey found that 74% of institutional LPs now rank realized distributions to paid-in capital (DPI) as the primary evaluation criterion for manager continuation and follow-on fund commitments; a decade earlier, that share was closer to 40%. DPI measures how much cash a fund has actually returned to investors relative to capital invested, and it's the hardest measure of fund performance because it can't be manipulated through unrealized portfolio markups, continuation vehicles, or secondary sales that don't generate new cash for the underlying LP. A fund with 1.0x DPI has returned the capital LPs put in, a fund with 2.0x DPI has doubled the capital in realized distributions, and most institutional LPs target 1.5-2.0x DPI within a fund's contractual lifecycle (typically 10-12 years).

Fund managers that can't demonstrate DPI track records can't raise new funds at historical scale, and that's visible across PE fundraising data. Global private equity exits peaked at 1,210 in 2021 and fell to 321 through December 22, 2025. Approximately 28,000 PE-backed companies globally remain unsold, representing roughly $3.2 trillion in unrealized net asset value per Bain & Company's 2025 year-end review. Median PE fund hold periods stretched from 4.2 years in 2010 to 6.8 years by 2023 per Cambridge Associates benchmark data, and the stretch isn't random; it's fund managers holding assets longer because exit markets have been weaker, hoping that conditions improve enough to execute realized exits rather than taking lower prices now. LPs are pushing back against that extended-hold strategy, and the dominant LP evaluation criterion shifted to realized distributions because of frustration with fund managers who've been unable to generate cash returns at historical rates. Why does this matter for ophthalmology specifically?

The 2017-2019 Cohort That Can't Exit

American ophthalmology saw a concentrated wave of PE platform formations between 2017 and 2019. EyeCare Partners (originally formed 2015, recapitalized by Partners Group in 2020), EyeSouth Partners (Olympus Partners 2022), Vision Innovation Partners (Gryphon, acquired from Centre 2022), American Vision Partners (H.I.G. Capital), Unifeye Vision Partners (Waud Capital), Spectrum Vision Partners, US Eye, Eye Health America (LLR Partners), and several smaller platforms all formed or were recapitalized within that window. Standard PE fund lifecycles run 10-12 years, with a 5-6 year investment period followed by a 5-6 year harvest and exit period, so platforms formed in 2017-2019 were expected to hit exit cycle during 2022-2025. That timing collided exactly with the broader exit environment collapse and the intensifying LP DPI pressure.

EyeCare Partners completed an out-of-court liability management exercise in April-May 2024, with first-lien debt having traded at roughly 54 cents on the dollar ahead of the restructuring, and Partners Group and existing lenders injected $275 million of new super-priority capital with maturities extended to 2027. This wasn't an exit; it was a restructuring designed to extend the runway until exit conditions improve. Vision Innovation Partners executed its 27th add-on acquisition in early 2026, and the platform has continued adding practices at a steady pace, but VIP has not executed a clean exit. Continuing to add practices extends hold period further, which works for the sponsor but tests LP patience. American Vision Partners acquired Evernorth Care Group's vision services from Cigna in August 2024, expanding AVP's footprint, but the platform faces an ongoing whistleblower complaint filed by Dr. Charles Mayron in February 2025 alleging patient-safety issues; the case is not resolved, and it complicates the exit narrative. Unifeye Vision Partners announced a new CEO in October 2025 (Mark Garvin, replacing Martin Rash who became Executive Chair) and took growth capital from Morgan Stanley Private Credit and PGIM in May 2025; a PE platform taking growth capital at that stage of the lifecycle, rather than pursuing a clean exit, typically signals that exit conditions aren't supporting the sponsor's target valuation. Eye Health America continued sponsor-to-sponsor add-on acquisitions, including the February 2025 acquisition of Quigley Eye Specialists from New Harbor Capital, working within the shrinking secondary market but not generating realized distributions to LPs at the platform level.

The pattern is direct. Most of the cohort is in some form of stabilization, restructuring, continuation, or hold-period extension rather than clean exit. Two exceptions exited successfully: Retina Consultants of America sold to Cencora for $4.4 billion cash plus up to $500 million in earn-out on January 2, 2025 (a strategic exit to a pharmaceutical distributor at 18.4x EBITDA), and PRISM Vision sold 80% to McKesson for $850 million in April 2025, also a strategic exit. Both went to pharmaceutical distributors rather than secondary PE sponsors. The structural point is that the exits that did happen in ophthalmology went to strategic corporate buyers at strategic multiples, while the sponsor-to-sponsor secondary market that historically absorbed PE platforms didn't show up for the ophthalmology cohort at required multiples. Most of the 2017-2019 cohort is stuck without a clear path to realized distributions for LPs.

Why Strategic Exits Won't Rescue the Whole Cohort

The Cencora and McKesson acquisitions generated significant realized distributions for their specific sponsor LPs: RCA's sponsors (Webster Equity Partners) and PRISM's sponsors (Quad-C Management) generated meaningful DPI on those transactions. Strategic corporate demand is bounded, however. Cencora won't buy three more RCA-equivalents, McKesson won't buy three more PRISM-equivalents, Cardinal Health's specialty acquisition budget is focused on urology and gastroenterology rather than ophthalmology, and Humana/CenterWell's priorities are in primary care. The strategic corporate buyer class can absorb roughly one trophy platform per major pharmaceutical distributor, which translates to 2-4 strategic exits across the ophthalmology PE cohort, leaving the remaining 6-10 platforms without an obvious strategic corporate exit path.

Sponsor-to-sponsor sales historically absorbed PE platforms in this position, but the broader exit market's weakness and LP DPI pressure have constrained that channel. A secondary PE buyer asked to acquire an ophthalmology platform at 2025-2026 multiples would need to see a path to their own exit at higher multiples within a 5-year hold period, and that path isn't obvious given the current environment. The math creates forced-seller dynamics across the stuck portion of the cohort. Platforms that can't exit at target multiples face a choice: restructure debt and extend hold periods (EyeCare Partners), continue operating and hope conditions improve (VIP, EHA), take growth capital in lieu of exits (Unifeye), or eventually liquidate at discounted valuations. LP pressure intensifies that dynamic: LPs who've been waiting 6-8 years for realized distributions are increasingly willing to accept partial exits, continuation vehicles, or discounted valuations rather than wait further, which creates selling pressure at the platform level and at the practice level within platforms.

What the Forced Exits Mean for the Specialty

The LP cash-return pressure cycle doesn't just constrain new PE platform formation; it also creates forced-seller dynamics across existing platforms. Practices within stuck PE platforms, even high-performing practices, may be sold off individually or in bundles to generate partial realized distributions for LPs, and physician rollover equity holders within those platforms face value uncertainty as platform-level exits get delayed or restructured. Secondary market practices (ophthalmology practices that were acquired by PE platforms in 2018-2022 and are now potentially available again through platform restructurings) represent one subset of the opportunity that patient-capital operators can absorb in 2026-2028.

Independent practices that haven't yet been acquired by PE represent the larger structural opportunity. The fundraising collapse means new PE platforms won't be forming at historical rates to compete for those practices, the exit environment weakness means existing PE platforms are inward-focused on their own restructuring rather than aggressive on new acquisitions, and the combination creates structural space for patient-capital operators to acquire independent practices in 2026-2028 with less competition from PE than at any point since the specialty's consolidation wave began in 2017.

The Handoff Between Capital Eras

For two decades, institutional LP capital flowing through PE fund structures dominated American healthcare consolidation. Fund formation, platform building, LBO acquisitions, integration, and exit cycles built the specialty-consolidation industry across cardiology, orthopedics, dermatology, dental, veterinary, and ophthalmology. That era is ending, not because LP capital is leaving healthcare, but because LP capital is demanding a different set of return characteristics than PE fund structures have been able to deliver through 5-year hold periods and forced-exit cycles. When the dominant LP priority shifts to realized cash returns over unrealized IRR markups, the capital structure that depends on exit-cycle execution has a structural problem that can't be solved by extending hold periods.

The capital structure that actually matches long-horizon physician ownership is the structure that patient-capital operators have always used: direct investment in operating businesses, permanent-hold intent, compound cash flow distribution over time, no exit cycle required because the underlying asset is valued for its durable cash flow rather than its terminal sale value. Pension funds didn't intend to kill PE's ophthalmology exit market; they intended to demand realized distributions from their fund managers, which is a reasonable institutional discipline. The downstream effect of that demand is that PE fund structures became structurally misaligned with specialties like ophthalmology where the underlying asset characteristics favor long-horizon ownership over 5-year exit cycles.

What comes next is the era where the capital structure matches the asset. Patient capital, permanent hold, physician-led, sized for the individual practice rather than the institutional fund platform. The capital class positioned for that era is already visible in 2025-2026 through operator-investor platforms, family office direct investment vehicles, and multi-generational holding company approaches to physician-led healthcare. The LPs who killed the PE ophthalmology exit created the conditions for a different capital class to absorb the specialty's long tail, and that capital class operates under different institutional disciplines, different time horizons, and different return expectations than the fund managers the LPs were previously backing. For American ophthalmology specifically, that capital class fits the underlying asset characteristics far better than the capital class it's replacing.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com